Expert Interview
A second look: Evaluating the Recent FDA Acceptance and Priority Review of Soleno Therapeutics' NDA for DCCR (Diazoxide Choline) in Prader-Willi Syndrome
Ticker(s): SLNOInstitution: University of Kansas
- Director, Division of Research and Genetics, Director, KUMC Genetics Clinic & ABMG Certified Clinical Geneticist and Clinical Cytogeneticist.
- Research interests include the genetics of obesity with emphasis on Prader-Willi syndrome and obesity-related disorders, autism, psychiatric and behavioral genetics, genotype-phenotype correlations and the natural history and delineation of rare and uncommon clinical genetics syndromes.
- Has published over 400 research articles, multiple book chapters and edited several journal issues and two textbooks.
The FDA granted Priority Review for the NDA of DCCR in PWS. Could you explain the significance of this designation, particularly for a condition as challenging as Prader-Willi Syndrome?
Added By: wilson_adminGiven that hyperphagia is a hallmark and life-threatening symptom of PWS, how could DCCR's ability to address hyperphagia change the standard of care for these patients?
Added By: wilson_adminBeyond hyperphagia, DCCR has shown promise in addressing other PWS symptoms such as aggressive behaviors and metabolic parameters. How important is it to have a treatment that can potentially address multiple aspects of this complex syndrome?
Added By: wilson_adminDeveloping treatments for rare diseases like PWS can be particularly challenging. What are some of the key hurdles that DCCR has successfully overcome in its clinical development, and what challenges remain?
Added By: wilson_adminCurrently, there are no approved therapies for hyperphagia in PWS. How does DCCR compare to other management strategies that are currently used off-label or in clinical practice?
Added By: wilson_adminThe FDA has planned an Advisory Committee meeting to discuss the application for DCCR. What are the potential implications of this meeting for the approval process, and what key points do you expect to be discussed?
Added By: wilson_adminThe PWS community has shown strong support for the development of DCCR. From your perspective, how might the approval of DCCR impact the daily lives of patients and their families?
Added By: wilson_adminWith a PDUFA target action date set for December 27, 2024, what are the next steps in the regulatory process, and how might the approval of DCCR reshape the treatment landscape for Prader-Willi Syndrome both in the U.S. and potentially internationally?
Added By: wilson_adminWhat are the impediments to using a generic source of diazoxide choline?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
